Trial · NCT07361549
Localized Injection of Lidocaine Via the Middle Meningeal Artery for Headache Treatment
NCT07361549, Phase 2, Recruiting, Daniel A Tonetti, MD
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Localized Injection of Lidocaine Via the Middle Meningeal Artery for Headache Treatment. Trials, record NCT07361549. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07361549
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Localized Injection of Lidocaine Via the Middle Meningeal Artery for Headache Treatment
- NCT number
- NCT07361549
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 80 participants, estimated
- Lead sponsor
- Daniel A Tonetti, MD
- Conditions
- Refractory Migraine, Headache
- Interventions
- Lidocaine (drug), Saline
- First posted
- 2026-01-23
- Last updated
- 2026-10-01
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Headache Impact Test-6 Scores (1 Month) | From baseline to 1 month follow-up | Difference in Headache Impact Test-6 Scores, with larger decreases in scores correlating with improvement in symptoms |
| Secondary | Change in Numeric Pain Scores | From baseline to periprocedural | Difference in Numeric Pain Scores (0-10), with larger decreases in scores correlating with improvement in symptoms |
| Secondary | Change in Migraine Disability Assessment Scores | From baseline to 3 month follow-up | Difference in Migraine Disability Assessment Scores, with larger decreases in scores correlating with improvement in symptoms |
| Secondary | Change in Headache Impact Test-6 Scores Over Time (2 Months) | From baseline to 2 month follow-up | Difference in Headache Impact Test-6 Scores, with larger decreases in scores correlating with improvement in symptoms |
| Secondary | Change in Headache Impact Test-6 Scores Over Time (3 Months) | From baseline to 3 month follow-up | Difference in Headache Impact Test-6 Scores, with larger decreases in scores correlating with improvement in symptoms |
| Secondary | Proportion with Substantial or Severe Headache Impact Test-6 Scores (1 Month) | From baseline to 1 month follow-up | Proportion of patients with substantial (56-59) or severe (\>= 60) Headache Impact Test-6 scores, with higher scores correlating with worser symptoms |
| Secondary | Proportion with Substantial or Severe Headache Impact Test-6 Scores (2 Months) | From baseline to 2 month follow-up | Proportion of patients with substantial (56-59) or severe (\>= 60) Headache Impact Test-6 scores, with higher scores correlating with worser symptoms |
| Secondary | Proportion with Substantial or Severe Headache Impact Test-6 Scores (3 Months) | From baseline to 3 month follow-up | Proportion of patients with substantial (56-69) or severe (\>= 60) Headache Impact Test-6 scores, with higher scores correlating with worser symptoms |
| Secondary | Proportion with Low Patient Global Impression of Change Scores (Post-Treatment) | From baseline to periprocedural | Proportion of patients with Patient Global Impression of Change Scores that are low (1-3), with lower scores correlating with better perception of symptoms |
| Secondary | Proportion with Low Patient Global Impression of Change Scores (1 Month) | From baseline to 1 month follow-up | Proportion of patients with Patient Global Impression of Change Scores that are low (1-3), with lower scores correlating with better perception of symptoms |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41608705 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07361549
GET https://conductscience.org/api/trials/v1/NCT07361549/registered